Endo, Perrigo Strike Deal In Nasal Spray Patent Suit

Law360 (August 20, 2019, 3:53 PM EDT) -- Endo Pharmaceuticals and Perrigo UK Finaco Ltd. Partnership told a Delaware federal court Tuesday they have reached a settlement to end allegations that Perrigo infringed patents covering Endo's vitamin B12 nasal spray, Nascobal.

The drug companies did not disclose any financial terms of the deal. But according to the proposed consent judgment, Endo and Perrigo agreed to dismiss with prejudice all claims that the Ireland-based company infringed six patents by applying to make a generic version of the medicine used to treat vitamin B12 deficiency. The illness can occur after someone undergoes bariatric surgery for weight loss.

Representatives for the parties...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS